Neurobiological Technologies - The 2009 Biotech Graveyard

Inside the mHealth Revolution with Welch Allyn: Realizing the Potential of Connected Devices
After launching a line of connected devices, Welch Allyn immediately viewed it as an oppor
Active Directory & the Cloud for Biotech & Pharma
Biotech and pharmaceutical companies are leaders cloud/SaaS technology adoption. This webi
Biomarkers and Translational Medicine in Early Phase Oncology Clinical Development (Part two of our three part series)
Increasingly, new technologies are making it possible to carefully identify sets of patien
Prepare Your Compliance Systems and Processes for the Physician Payments Sunshine Act
Beginning in 2012, pharmaceutical, biotechnology and medical device companies will be requ

October 28, 2009 — 8:17am ET | By Maureen Martino

Tools

Company: Neurobiological Technologies
Based: Emeryville, CA

What went wrong: Neurobiological Technologies' venom-based drug Viprinex for strokes failed a late-stage trial last year, sending the company into a tailspin. The company laid off most of its staff after the failure and hoped to find a buyer. But with no offers, the company had no choice but to close its doors.